A peptide stack is a marketing term for two or more peptides used together, and the controlled human evidence for any such pair comes from one place: physiology studies of the 1990s and 2000s in which a GH-releasing peptide and GHRH given together produced more growth hormone release than either alone, first in 18 normal men in 1990 [15, 16, 17]. No registered trial has evaluated CJC-1295 with ipamorelin, the most searched stack, and the only controlled study of BPC-157 with TB-500 is a 2026 rat model of 32 animals in which the study reported no additive benefit [5, 23].
Behind every searched stack sit four questions: why the combination is marketed, what the co-administration literature measured and in how many people, what a multi-ingredient preparation asks of a compounding pharmacy, and how the 503A rules and the October 2026 HHS interim policy apply to a blend. A table near the end lists what is published for each commonly searched stack. Combination decisions belong to the prescriber; ExaVeyra supplies the documented preparations a prescription calls for.
Supplier position
Under section 503A every bulk substance in a compounded preparation must qualify on its own, through a USP or NF monograph, as a component of an approved drug, or from the 503A bulks list, with a valid certificate of analysis for each [9]. As of 4 November 2026, CJC-1295, BPC-157, TB-500 and injectable GHK-Cu sit in FDA’s withdrawn-nominations table, ipamorelin appears there and in category 2 under 503B, and the draft HHS interim policy of 30 October 2026 covers six peptides only as single-ingredient products [10, 13]. A compounded blend is prepared by our 503A pharmacy partner only against a patient-specific prescription with every component eligible; non-catalog peptides are offered for IND-authorized clinical trials through our pharmacy partner, with the sponsor’s IND number, sponsor details and protocol confirmed before any supply; and the practitioner decides any use.
Understanding why combinations are marketed before any trial exists
Stacks are sold on mechanism. A GHRH analog acts at one receptor and a GH-releasing peptide at another, so a seller can describe two routes to the same hormone; a gastric peptide and an actin-binding fragment are described as two routes to tissue repair. Dominikowski and colleagues reported in 2026 that online self-administration protocols for GH-axis peptides carry uncertainty about composition, quantity and stacking practices that the peer-reviewed record does not resolve [2].
The reviews written for sports medicine physicians describe the same gap. Tewari and colleagues reported in 2026 that 67 percent of publications on six marketed peptides were animal studies and that human studies were a handful with weak controls [1], and Mendias and Awan discussed placebo and social media as mediators of the effects patients report [3]. A stack inherits the evidence of its weakest component and adds a question about the mixture.
GHRH plus GHRP co-administration physiology is the controlled human evidence
Bowers and colleagues reported in 1990 that the hexapeptide GHRP-6 given intravenously to 18 normal men released growth hormone in a graded fashion, and that GHRP given together with GHRH-(1-44) acted synergistically, producing more GH than either peptide alone [15]. Mild facial flushing lasting one to three minutes followed GHRH in 16 of the 18 men [15].
Arvat and colleagues reported in 1995 the same interaction for hexarelin with GHRH in six healthy men [16], and in 2001 compared ghrelin, hexarelin and GHRH alone and in combination, describing a ghrelin-receptor agonist acting with a GHRH-receptor agonist [17]. Sigalos and Pastuszak reviewed the class in 2018 and reported that secretagogues promote pulsatile GH release subject to feedback, with limited long-term outcome data [22].
Those studies measured acute hormone concentrations in a laboratory over hours. None measured recovery, body composition or any clinical outcome of a combination over weeks, and none used CJC-1295 or ipamorelin, which did not yet exist as marketed products. The physiology is real; the stack evidence that cites it is an extrapolation.
CJC-1295 and ipamorelin each have single-agent trials and no trial together
Teichman and colleagues reported in 2006 two randomized placebo-controlled trials of CJC-1295 alone in healthy adults, lasting 28 and 49 days, in which GH rose 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days and no serious adverse reactions [18]. Ionescu and Frohman reported in 2006 that GH pulsatility persisted during that continuous stimulation in healthy men [19].
Ipamorelin’s record is different in kind. Raun and colleagues described it in 1998 in rat pituitary cells, rats and swine as a GHRP-receptor agonist that did not raise ACTH or cortisol in swine, a paper with no human data [20]. The largest published human trial, Beck and colleagues in 2014, enrolled 117 patients after bowel resection (114 analyzed), randomized to intravenous ipamorelin or placebo, and reported no significant difference on the key efficacy endpoint [21].
ClinicalTrials.gov on 4 November 2026 returned a terminated 120-participant CJC-1295 trial and two completed ipamorelin trials of 117 and 320 participants, and a search for the two names together returned no record [23]. FDA’s page carries the ipamorelin entry in both tables and quotes a published study that identified serious adverse events including death when ipamorelin was given intravenously [10].
Several questions remain open in the published evidence
The combinations that search engines rank highest share one feature: the pair has never been tested as a pair in people. The points below set out what the published evidence does not yet show.
- No randomized human trial of any marketed two-peptide stack has been published; the GHRP plus GHRH studies measured acute hormone release in 6 to 18 volunteers, not an outcome [15, 16, 17].
- No registered trial has evaluated CJC-1295 with ipamorelin; each has single-agent records only [23].
- The only controlled study of BPC-157 with TB-500 is a four-week rat model of 32 animals, and the study reported that the combination conferred no additional benefit over either agent alone [5].
- No study of GHK-Cu combined with BPC-157 or TB-500, the so-called glow stack, was located; the GHK-Cu literature concerns skin and wound models of the single peptide [8].
- No published stability, compatibility or preservative data exist for a multi-peptide vial; the single-peptide formulation record for BPC-157 is itself described as rudimentary [7].
- Human safety data for the components remain scarce: the 2025 BPC-157 systematic review found none [6], and reviews of the secretagogue class report limited long-term outcomes [22].
Pharmaceutical compatibility governs any blend before pharmacology does
Two peptides in one vial share a pH, a buffer, a preservative and a storage condition, and each peptide has its own window for all four. Mateescu and colleagues reported in 2026 that the formulation record for BPC-157 alone is rudimentary, with no approved formulation and an undercharacterized pharmacokinetic profile [7]; a second peptide adds aggregation, adsorption and degradation questions that no published study has answered for a blend.
Sterility is the second question. Shehab and colleagues reviewed 19 outbreaks linked to compounded sterile preparations between 2001 and 2013, with at least 1,000 cases including deaths, and reported that breaches in aseptic processing and deficiencies in sterility and endotoxin testing were consistent findings [24]. The statute names the USP chapter on pharmacy compounding as a condition of 503A, and the USP nonsterile and sterile compounding chapters, 795 and 797, are the standards a state board holds a pharmacy to [9, 12].
Identity is the third. Janvier and colleagues reported purity between 5 and 75 percent for cysteine-containing peptides and arsenic and lead above ICH parenteral limits in falsified peptide products bought online [25], and Gudeman and colleagues noted that compounded preparations are exempt from good manufacturing practice regulations, so quality rests on the pharmacy’s own certificate of analysis and testing [26]. Mixing two unverified peptides multiplies the unknowns.
The 503A rules read a multi-ingredient preparation one bulk substance at a time
FDA’s bulks page states the test for each bulk substance a 503A compounder uses: a USP or NF monograph, a component of an approved drug, or the 503A bulks list, with a valid certificate of analysis from an FDA-registered establishment [9]. A preparation with three bulk substances must pass that test three times, and a blend that contains one withdrawn or category 2 substance is a preparation that contains an ineligible substance.
As of 4 November 2026 the components of the searched stacks sit as follows: CJC-1295, BPC-157, TB-500 and injectable GHK-Cu in the withdrawn-nominations table; ipamorelin in that table and in category 2 under 503B; GHK-Cu for non-injectable routes back in category 1 since 14 May 2026 [10, 11]. Compounded drugs are not FDA-approved, as the agency’s questions and answers page states, and state boards hold day-to-day oversight of the pharmacy [12].
The HHS draft interim policy published 30 October 2026 answers the blend question directly for its six peptides: condition 7 requires that a product within the policy contain only a single active pharmaceutical ingredient from the list, with the stated reason that single-ingredient products let adverse events be attributed [13]. The policy is a draft open for comment to 13 November 2026, is not binding, and does not name CJC-1295, ipamorelin or GHK-Cu [13, 14].
A table of commonly searched stacks and what is published for each
The table lists the stacks people search most, the controlled evidence located for the combination as such, the 503A position of each component on 4 November 2026, and the sport status. Every row describes the published record, and the order carries no ranking.
| Searched stack | Controlled evidence for the combination | 503A position of the components (4 Nov 2026) | WADA 2026 |
|---|---|---|---|
| CJC-1295 with ipamorelin | None; single-agent trials only (two CJC-1295 RCTs in healthy adults; a 117-patient ipamorelin RCT with no difference from placebo) [18, 21, 23] | Both nominations withdrawn; ipamorelin also category 2 under 503B; neither on the HHS list [10, 13] | Both S2.2.4, prohibited at all times [27] |
| Sermorelin with ipamorelin (GHRH analog with a GHRP) | Mechanism only: GHRP plus GHRH synergy in 18 men (1990) and 6 men (1995), acute hormone release [15, 16] | Sermorelin compounded by our pharmacy partner to prescription; ipamorelin withdrawn [10] | Both S2.2.4 [27] |
| BPC-157 with TB-500 | One 2026 rat study, 32 animals: no additive benefit reported [5] | Both withdrawn nominations; both on the HHS interim list as single-ingredient products only [10, 13] | S0 and S2.3 [27] |
| GHK-Cu with BPC-157 and TB-500 (glow stack) | None located; GHK-Cu literature is single-peptide skin and wound work [8] | Topical GHK-Cu category 1 since 14 May 2026, available as topical 503A preparations compounded to prescription; the other two as above [11, 13] | BPC-157 S0, TB-500 S2.3 [27] |
| Tesamorelin with ipamorelin | None for the pair; tesamorelin is an approved drug with phase 3 trials, ipamorelin as above [4, 21] | Tesamorelin approved; ipamorelin withdrawn [10] | Both S2.2.4 [27] |
A prescription for one documented preparation is where a program starts
A practice asked for a stack can answer with the record: one 1990 physiology study behind the secretagogue pairing, one 2026 rat study behind the repair pairing, and a 503A test that each component passes or fails on its own. ExaVeyra’s catalog peptides are compounded by our 503A pharmacy partner against a patient-specific prescription, topical GHK-Cu is available as topical 503A preparations compounded to prescription, and any blend is prepared only against a patient-specific prescription with every component eligible.
Anyone may apply or ask the scientific team a question without an NPI, and NPI verification, which takes 1 to 3 business days, gives access to the practitioner portal, product documentation and pricing. The first trials of several single peptides opened in 2026, and a practice that keeps one documented preparation per prescription will be ready to read combination evidence when it is finally produced.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. Published online ahead of print. PMID 42578445. doi:10.1177/03635465261464420PRISMA scoping review of six marketed peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu) across musculoskeletal tissues. Carries in this article: 67 percent of publications were animal studies, human studies were a handful with weak controls, and the authors reported significant heterogeneity in quantity and route, the reason no combination has a controlled human record. Disclosure: not stated in the PubMed record.
- 2.Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PMID 42395176. doi:10.3389/fendo.2026.1822475Narrative review contrasting peer-reviewed pharmacology of GHRH analogs, secretagogues and GH fragments with online self-administration protocols. Carries in this article: the authors name uncertainty about composition, quantity and stacking practices in unregulated supply chains, and stratify the agents from regulatory-grade trial data to a complete absence of human studies. Disclosure: no commercial relationships declared.
- 3.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID 41966639. doi:10.1007/s40279-026-02437-0Narrative review covering BPC-157, CJC-1295, GHK-Cu, ipamorelin, sermorelin, tesamorelin, thymosin beta-4 and TB-500 among others. Carries in this article: favorable animal outcomes beside scarce human safety data, and the authors’ discussion of placebo and social media as mediators of perceived effect. Disclosure: one author reports unrelated consulting fees.
- 4.Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026;14(5). PMID 42160466. doi:10.2106/JBJS.RVW.26.00027Structured narrative review of human and translational studies from January 2020 to August 2025. Carries in this article: growth hormone axis secretagogues (CJC-1295, ipamorelin, tesamorelin) and regenerative peptides remained investigational with product quality concerns and antidoping restrictions. Funding: a research institute listed in the record.
- 5.Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926. doi:10.52312/jdrs.2026.2951Randomized four-arm rat study; 32 rats, eight per group (control, BPC-157, TB-500, both), four weeks after Achilles transection and repair. Carries in this article: the only controlled study of a marketed two-peptide combination located, which reported that the combination conferred no additional benefit over either agent alone. Disclosure: none stated in the PubMed record.
- 6.Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID 40756949. doi:10.1177/15563316251355551Systematic review to June 2024; 36 studies, 35 preclinical and 1 clinical. Carries in this article: the human record for the most searched stack component is one retrospective series of 12 patients, and no clinical safety data were found. Disclosure: several authors declare industry relationships.
- 7.Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. PMID 42198317. doi:10.3390/pharmaceutics18050625Narrative review of formulation science and translational barriers for BPC-157. Carries in this article: pharmaceutical development remains rudimentary with no approved formulation, and the physicochemical and stability questions of a single peptide precede any question about combining two in one vial. Funding: a university in Romania; no conflicts declared.
- 8.Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730. doi:10.1155/2015/648108Narrative review by the peptide’s discoverer of GHK and GHK-Cu biology in skin. Carries in this article: the mechanism literature behind the so-called glow stack component, which concerns skin and wound models and includes no study of GHK-Cu combined with BPC-157 or TB-500. Disclosure: the first author holds commercial interests in GHK products.
- 9.U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Content current as of 05/14/2026; verified 4 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-actAgency compounding page (CDER). Carries in this article: each bulk substance used must comply with a USP or NF monograph and the USP chapter on pharmacy compounding, be a component of an approved drug, or appear on the 503A bulks list, with a valid certificate of analysis from an FDA-registered establishment, a test applied substance by substance.
- 10.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 of the interim policies, with the table of substances nominated but withdrawn). Content current as of 04/22/2026; verified 4 November 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risksAgency compounding page (CDER). Carries in this article: CJC-1295, BPC-157, TB-500 and GHK-Cu for injectable routes sit in the withdrawn-nominations table; ipamorelin acetate appears in both tables, and the agency wrote that a published study identified serious adverse events including death when ipamorelin was given intravenously; ibutamoren remains in category 2 with a trial stopped early for a heart failure signal.
- 11.U.S. Food and Drug Administration. 503A Bulk Drug Substances Categories: Category 1 (Bulk Drug Substances Under Evaluation) and Category 3. PDF updated May 14, 2026; downloaded and verified 4 November 2026. https://www.fda.gov/media/94155/downloadAgency list document (CDER). Carries in this article: GHK-Cu (except for injectable routes of administration) returned to category 1 on 14 May 2026, and the category 1 list on that date contains no other peptide from the stacks people search.
- 12.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Content current as of 09/16/2025; verified 4 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answersAgency explainer page (CDER). Carries in this article: compounded drugs are not FDA-approved and the agency does not verify their safety, effectiveness or quality before marketing, and state boards of pharmacy generally hold day-to-day oversight of 503A pharmacies.
- 13.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B. 16 pages; read on hhs.gov 4 November 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdfDraft interim policy document announced at 91 FR 68526 on 30 October 2026. Carries in this article: condition 7 requires that a compounded product within the policy contain only a single active pharmaceutical ingredient from the six-peptide list, with the stated reason that single-ingredient products make adverse events attributable; condition 10 requires compounding that is not under insanitary conditions; the route limits are per peptide.
- 14.U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. Federal Register. 2026;91:68526-68527 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496), published 30 October 2026, comments to 13 November 2026; verified 4 November 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substancesFederal Register notice of availability. Carries in this article: the policy is a draft, establishes no rights and is not binding, applies to 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians, and lasts until rulemaking decides each peptide’s place on the bulks list.
- 15.Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. PMID 2108187. doi:10.1210/jcem-70-4-975Controlled physiology study in 18 normal men given the hexapeptide GHRP-6 alone and with GHRH-(1-44) by intravenous bolus. Carries in this article: the original demonstration that a GHRP and GHRH given together produced GH release greater than either alone, the physiological basis every secretagogue stack borrows; mild facial flushing followed GHRH in 16 of 18 men. Funding: NIH.
- 16.Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology. 1995;61(1):51-6. PMID 7731498. doi:10.1159/000126827Controlled physiology study in two groups of six healthy men: the first tested hexarelin with GHRH and somatostatin, the second with neuroactive agents. Carries in this article: the European replication of GHRP and GHRH interaction in humans, in the six men of the first experiment. Disclosure: two authors affiliated with the peptide’s developer.
- 17.Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-74. PMID 11238504. doi:10.1210/jcem.86.3.7314Controlled physiology study in healthy volunteers comparing ghrelin, hexarelin and GHRH alone and in combination. Carries in this article: the receptor logic behind secretagogue combinations, a ghrelin-receptor agonist acting with a GHRH-receptor agonist, measured as acute hormone release in a laboratory setting rather than as any clinical outcome.
- 18.Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. doi:10.1210/jc.2005-1536Two randomized placebo-controlled double-blind ascending-exposure trials of 28 and 49 days in healthy adults aged 21 to 61 at two sites. Carries in this article: CJC-1295 alone raised GH 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9 to 11 days with an estimated half-life of 5.8 to 8.1 days; no serious adverse reactions were reported; no arm combined it with a GHRP. Funding: the developer.
- 19.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID 17018654. doi:10.1210/jc.2006-1702Physiology study with 20-minute overnight sampling in healthy men aged 20 to 40 before and one week after a single CJC-1295 exposure. Carries in this article: GH secretion increased with preserved pulsatility, a single-agent finding. Funding: NIH clinical research center support.
- 20.Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822. doi:10.1530/eje.0.1390552Preclinical pharmacology paper from the developer: rat pituitary cells, anesthetized rats and conscious swine. Carries in this article: ipamorelin released GH through the GHRP receptor with potency similar to GHRP-6 and, unlike GHRP-2 and GHRP-6, did not raise ACTH or cortisol in swine, the selectivity claim that marketing repeats; no human data appear in the paper. Disclosure: authors employed by the developer.
- 21.Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID 25331030. doi:10.1007/s00384-014-2030-8Multicenter double-blind placebo-controlled phase 2 trial (NCT00672074); 117 patients enrolled, 114 analyzed, intravenous exposure for up to seven days. Carries in this article: the largest published randomized human study of ipamorelin, in which the trial reported no significant difference from placebo on the key efficacy endpoint and treatment-emergent adverse events in 87.5 percent of the ipamorelin group and 94.8 percent of placebo. Funding: the sponsor.
- 22.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID 28400207. doi:10.1016/j.sxmr.2017.02.004Narrative review of human studies of GH secretagogues including GH-releasing peptides and ibutamoren. Carries in this article: the physiological account that secretagogues promote pulsatile GH release subject to feedback, and the observation that long-term outcome data are limited. Funding: NIH training support; no conflicts reported.
- 23.ClinicalTrials.gov. Records returned on 4 November 2026 for CJC-1295 or ipamorelin: NCT00267527 (CJC-1295 in HIV-associated visceral obesity, phase 2, 120 participants, terminated); NCT00672074 (ipamorelin for postoperative ileus, phase 2, 117 participants, completed); NCT01280344 (ipamorelin for gastrointestinal recovery, randomized phase 2, 320 participants, completed, no posted results); NCT07717866 (an observational cohort, first posted July 2026, that lists ipamorelin among several supplementation agents, not a trial of ipamorelin). A search for CJC-1295 AND ipamorelin returned no record. https://clinicaltrials.gov/search?term=CJC-1295%20OR%20ipamorelinRegistry records read through the v2 API. Carries in this article: each agent has its own registered single-agent trials and no registered trial has evaluated the two together, the finding behind the table row for the most searched secretagogue stack.
- 24.Shehab N, Brown MN, Kallen AJ, Perz JF. U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned. J Patient Saf. 2018;14(3):164-173. PMID 26001553. doi:10.1097/PTS.0000000000000188Review of CDC, FDA and published outbreak records; 19 outbreaks linked to pharmacy-compounded sterile preparations with at least 1,000 cases including deaths. Carries in this article: breaches in aseptic processing and deficiencies in sterility and endotoxin testing were consistent findings, the sterility question any multi-ingredient injectable blend must answer. Funding: CDC intramural.
- 25.Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. PMID 30029448. doi:10.1016/j.talanta.2018.06.023Laboratory analysis of the ten most frequently encountered falsified peptide products from suspected illegal internet pharmacies. Carries in this article: purity between 5 and 75 percent for cysteine-containing peptides and arsenic and lead above ICH parenteral limits, the identity problem that multiplies when two or three unverified peptides are mixed. Disclosure: public health institute authors.
- 26.Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. PMID 23526368. doi:10.1007/s40268-013-0005-9Narrative review of compounding oversight. Carries in this article: compounded preparations are exempt from good manufacturing practice regulations and quality testing is inconsistent, so stability and compatibility of a blend rest on the pharmacy’s own documentation. Disclosure: authors employed by a pharmaceutical manufacturer.
- 27.World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard, in force 1 January 2026 (S0; S2.2.4 Growth hormone releasing factors; S2.3 Growth factors and growth factor modulators). PDF read on wada-ama.org, verified 4 November 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdfInternational standard, English text. Carries in this article: every component of the stacks in the table is prohibited at all times in sport, with CJC-1295, sermorelin, tesamorelin and ipamorelin named under S2.2.4, BPC-157 under S0 and TB-500 under S2.3.